Search research articles
Contact Us
Filters
Showing results (191-200 of 202) with videos related to
Page
of 21
Sort By:
Scientific Reports
|
November 26, 2022
Succinate prodrugs in combination with atropine and pralidoxime protect cerebral mitochondrial function in a rodent model of acute organophosphate poisoning
Sarah Piel, Joanna I Janowska, J Laurenson Ward, et al.
Journal of Internal Medicine
|
February 20, 2014
Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival
J Hansson, M R Galanti, M-P Hergens, et al.
Molecular and Cellular Biochemistry
|
October 25, 2022
Succinate prodrugs as treatment for acute metabolic crisis during fluoroacetate intoxication in the rat
Sarah Piel, Joanna I Janowska, J Laurenson Ward, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Iscience
|
February 18, 2026
The succinate prodrug NV354 prevents brain lesions and late-stage motor dysfunction in mitochondrial complex I deficiency
Meagan J McManus, Yi Zhu, Cesar Alves, et al.
The EMBO Journal
|
February 21, 2015
The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1β
Hidetoshi Fujita, Naoko Yagishita, Satoko Aratani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
Journal of the National Cancer Institute
|
September 30, 2010
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study
F Demenais, H Mohamdi, V Chaudru, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 202) with videos related to
Sort By:
Page
of 21
Scientific Reports
|
November 26, 2022
Succinate prodrugs in combination with atropine and pralidoxime protect cerebral mitochondrial function in a rodent model of acute organophosphate poisoning
Sarah Piel, Joanna I Janowska, J Laurenson Ward, et al.
Journal of Internal Medicine
|
February 20, 2014
Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival
J Hansson, M R Galanti, M-P Hergens, et al.
Molecular and Cellular Biochemistry
|
October 25, 2022
Succinate prodrugs as treatment for acute metabolic crisis during fluoroacetate intoxication in the rat
Sarah Piel, Joanna I Janowska, J Laurenson Ward, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Iscience
|
February 18, 2026
The succinate prodrug NV354 prevents brain lesions and late-stage motor dysfunction in mitochondrial complex I deficiency
Meagan J McManus, Yi Zhu, Cesar Alves, et al.
The EMBO Journal
|
February 21, 2015
The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1β
Hidetoshi Fujita, Naoko Yagishita, Satoko Aratani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
Journal of the National Cancer Institute
|
September 30, 2010
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study
F Demenais, H Mohamdi, V Chaudru, et al.
Page
of 21